Advertisement

Cancer Immunology, Immunotherapy

, Volume 64, Issue 7, pp 923–930 | Cite as

Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6–8, 2014

  • Björn-Philipp Kloke
  • Andrea Mahr
  • Robert A. Jabulowsky
  • Sarah Kutscher
  • Richard Rae
  • Cedrik M. Britten
Meeting Report

Introduction

In December 2013, the Science magazine has designated cancer immunotherapy (CIMT) as the breakthrough of the year mainly due to clinical success stories in the area of checkpoint inhibitory antibodies and cellular gene therapy. This year’s CIMT 2014 meeting covered these recent success stories as well as additional technologies and therapeutic concepts that may form the base for the next wave of innovation to reach patients in the near future. Reflecting the increasing attention the field is attracting, the annual meeting of the Association for CIMT could observe yet another rise in the number of international participants (n = 950). A total of 85 used the opportunity to give lectures and 321 presented their cutting-edge innovations in poster sessions. CIMT offered a sizable stage for the dissemination and intensive discussion of research and development efforts in the areas of tumor vaccination, combination therapy, tumor microenvironment, immunoguiding,...

Keywords

CIMT 2014 Cancer immunotherapy Cancer immunology Tumor vaccination 

Abbreviations

Ab

Antibody

ACT

Adoptive cellular transfer

ADCC

Antibody-dependent cellular cytotoxicity

ATG

Anti-thymocyte globulin

BTN3A1

Butyrophilin 3A1

CAR

Chimeric antigen receptor

CIMT

Association for Cancer Immunotherapy

CIP

CIMT Immunoguiding Program

CT

Cancer–testis

CTLA-4

Cytotoxic T-lymphocyte-associated protein 4

CTL

Cytotoxic T lymphocytes

CTX

Cyclophosphamide

DNAM-1

DNAX Accessory Molecule-1

FasL

Fas ligand

IFA

Incomplete Freud’s adjuvant

IL-10

Interleukin 10

LP

Long peptides

PD-1

Programmed cell death 1

PD-L1

Programmed death-ligand 1

PGE2

Prostaglandin E2

RRG

CIMT Regulatory Research group

SP

Short peptides

Teff

T effector cells

TERS

TCR-engineered reference samples

TIGIT

T cell immunoreceptor with Ig and ITIM domains

Treg

T regulatory cells

VEGF-A

Vascular endothelial growth factor A

Notes

Acknowledgments

The authors would like to thank Christiane Wellié-Reeve (Mainz, Germany) for carefully proof reading the meeting report. Selected sessions of the CIMT meeting were made possible by research grants from the German Bundesministerium für Bildung and Forschung (BMBF Grant: 031A018). The CIMT working group CIP receives support for educational activities by the Wallace Coulter Foundation (Florida, USA).

Conflict of interest

The authors declare that they have no conflict of interest. Cedrik M. Britten has been the co-organizer of the meeting. Björn-Philipp Kloke has been the co-organizer of the CIMT Endeavour workshop.

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Björn-Philipp Kloke
    • 1
  • Andrea Mahr
    • 2
  • Robert A. Jabulowsky
    • 1
  • Sarah Kutscher
    • 2
  • Richard Rae
    • 3
  • Cedrik M. Britten
    • 1
    • 3
  1. 1.BioNTech RNA Pharmaceuticals GmbHMainzGermany
  2. 2.Immatics Biotechnologies GmbHTübingenGermany
  3. 3.TRON – Translational Oncology at the University Medical Center of the Johannes Gutenberg UniversityMainzGermany

Personalised recommendations